regenxbio.com (RGNX): Growth-Adjusted P/E Ratio
The P/E to growth rate dynamics on the GURU.Markets chart, where 0.00 shows the current metric value, indicate that assets for patients with rare retinal pathologies are undervalued. REGENXBIO Inc. (RGNX) revenues are based on licenses for the use of AAV vectors. The development of drugs for neurological diseases via the NAV platform mitigates risks. Stringent FDA control creates a defensive barrier for this ecosystem.
Metric breakdowns and analytics for REGENXBIO Corp (RGNX)
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- business debt structure and liquidity details:
- net income and valuation multiples indicators:
RGNX - Net Profit|Future Profit REGENXBIO Inc.|RGNX - Price to Earnings Ratio|Market Cap to Projected Earnings regenxbio.com|RGNX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation REGENXBIO Corp|RGNX - Operating profit EBITDA|Net earnings per share for the trailing year REGENXBIO|RGNX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months regenxbio.com|RGNX - Net earnings per share growth this year|Projected earnings per share growth rate for next year REGENXBIO Inc.
- issuer revenue and sales details:
Summary company analytics:Regenxbio, RGNX
The PEG ratio compares the earnings multiple to the growth rate, identifying an undervalued asset when the value falls below one. By analyzing the current PEG valuation of REGENXBIO Inc. (RGNX), an investor can assess how effectively the NAV platform capitalization and gene therapy successes are priced in to distinguish the fundamental potential of REGENXBIO Inc. (RGNX) from speculative growth.
Competing companies
PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx|Price to Earnings Adjusted for Growth Rate beamtx.com BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x TXG|Company Value to Earnings Growth Ratio NTLA (Intellia)|Stoke Corp - PEG Multiple|BLFS: Price/Earnings to Growth Ratio|WVE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Maze Tx (MAZE)|Price/Earnings to Growth Ratio Sionna Therapeutics|Growth-Adjusted P/E Ratio PRME (Prime Medicine Corp)|PEG Multiple TSHA|PEG Multiple uniqure.com (QURE)|Price/Earnings to Growth Ratio MeiraGTx PLC MGTX|SLDB - Price/Earnings to Growth Multiple|Ocugen, Inc. - PEG Multiple|PACB (Pacific Biosciences of California) - Growth-Adjusted P/E Ratio|BNTC: PEG Multiple|DSGN - Growth-Adjusted Market Cap to Net Income|RCKT (Rocket Pharma) - PEG Multiple|Price/Earnings to Growth Ratio FDMT|Price/Earnings to Growth Ratio Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Growth-Adjusted P/E Ratio|editasmedicine.com - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income silence-therapeutics.com (SLN)|PRQR: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate codexis.com|SGMO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income
